Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma

F. Errington, C. L. White, K. R. Twigger, A. Rose, K. Scott, L. Steele, L. J. Ilett, R. Prestwich, H. S. Pandha, M. Coffey, P. Selby, R. Vile, K. J. Harrington, A. A. Melcher

Research output: Contribution to journalArticlepeer-review

76 Scopus citations


Reovirus is a promising unmodified double-stranded RNA (dsRNA) anti-cancer oncolytic virus, which is thought to specifically target cells with activated Ras. Although reovirus has been tested in a wide range of preclinical models and has entered early clinical trials, it has not previously been tested for the treatment of human melanoma. Here, we show that reovirus effectively kills and replicates in both human melanoma cell lines and freshly resected tumour; intratumoural injection also causes regression of melanoma in a xenograft in vivo model. Reovirus-induced melanoma death is blocked by caspase inhibition and is dependent on constituents of the Ras/RalGEF/p38 pathway. Reovirus melanoma killing is more potent than, and distinct from, chemotherapy or radiotherapy-induced cell death; a range of inflammatory cytokines and chemokines are released by infected tumour cells, while IL-10 secretion is abrogated. Furthermore, the inflammatory response generated by reovirus-infected tumour cells causes bystander toxicity against reovirus-resistant tumour cells and activates human myeloid dendritic cells (DC) in vitro. Hence, reovirus is suitable for clinical testing in melanoma, and may provide a useful danger signal to reverse the immunologically suppressive environment characteristic of this tumour.

Original languageEnglish (US)
Pages (from-to)1257-1270
Number of pages14
JournalGene Therapy
Issue number18
StatePublished - 2008

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics


Dive into the research topics of 'Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma'. Together they form a unique fingerprint.

Cite this